Neurocrine Biosciences | NBIX - Ebitda





Ebitda Veränderung Datum
AbbVie USD 5.37B 1.85B 2025-12
Acadia Pharmaceuticals USD 20.31M 15.44M 2025-12
Agios Pharmaceuticals USD -120.31M 4.82M 2025-12
ALKERMES USD 80.26M 20.05M 2026-03
Alnylam Pharmaceuticals USD 145.22M 236.56M 2025-12
Amgen USD 5.14B 775M 2025-12
Biogen USD 649.7M 76.5M 2026-03
BioMarin Pharmaceutical USD 146.05M 170.22M 2026-03
Cytokinetics USD -169.32M 19.48M 2026-03
Exelixis USD 258.29M 15.43M 2026-03
Gilead Sciences USD 3.02B 1.01B 2025-12
Halozyme Therapeutics USD 219.57M 197.66M 2026-03
Incyte USD 367.97M 46.53M 2026-03
Ionis Pharmaceuticals USD -200.02M 42.89M 2025-12
Nektar Therapeutics USD -31.81M 70K 2023-09
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
Pfizer USD 5.99B 5.23B 2026-03
Prothena USD -39.53M 12.25M 2025-09
Regeneron Pharmaceuticals USD 1.2B 718.4M 2025-12
Repligen USD 40.01M 469K 2026-03
Rigel Pharmaceuticals USD -4.17M 798K 2023-09
Sarepta Therapeutics USD -252.2M 84.16M 2025-12
Teva Pharmaceutical Industries USD 1.06B 582M 2026-03
Ultragenyx Pharmaceutical USD -99.43M 57.35M 2025-12
Vertex Pharmaceuticals USD 1.19B 195.3M 2026-03
Xoma USD 2.52M 7.98M 2024-06